Nucleai secures $14 million funding led by M Ventures to advance its spatial AI biomarker for clinical enrollment

Apr 03, 2024•over 1 year ago

Amount Raised

$14 Million

ChicagoArtificial IntelligenceHealth CareSoftware

Investors

Sanofi VenturesSection 32M Ventures

Description

Nucleai has secured a $14 million investment led by M Ventures, enabling the deployment of its AI algorithms for the prospective enrollment of patients in clinical trials and accelerating the deployment of Nucleai’s spatial analysis technology.

Company Information

Company

Nucleai

Location

Chicago, Illinois, United States

About

Nucleai is the leading AI-powered spatial biomarker company, driving innovation at the intersection of technology and healthcare. Leveraging military intelligence-grade geospatial analytical methods, it intercepts, interprets, and analyzes complex cellular conversations and spatially oriented interactions within tissue samples, translating them into actionable insights. Nucleai’s platform empowers pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. Nucleai's investors include Section 32, Sanofi, Vertex Ventures, M Ventures, and Debiopharm Innovation Fund. It is headquartered in Israel and Chicago. For more information, please visit www.nucleai.ai.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech